Compounds having activity as LRRK2 inhibitors are disclosed. The compounds are of formula (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds are also disclosed.
本发明公开了具有
LRRK2 抑制剂活性的化合物。这些化合物为式(I)化合物,包括其立体异构体、同系物、药学上可接受的盐和原药。还公开了与制备和使用此类化合物相关的方法,以及包含此类化合物的药物组合物。